You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲藥業(0867.HK)連續第二日大漲 股價創逾2個月新高
格隆匯 01-11 11:57
格隆匯1月11日丨繼昨日收漲4.34%後,康哲藥業(0867.HK)今日盤中再度漲超7%至14.54港元,股價創2021年10月底以來新高,最新市值355億港元。消息面上,1月4日,康哲藥業創新藥甲氨蝶呤注射液(預充式)擬用於治療嚴重、頑固、致殘性銀屑病和其它自身免疫性疾病的上市許可申請獲中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)授予優先審評資格,這是繼2021年12月8日該產品中國上市許可申請獲受理後的又一新進展。1月10日,康哲藥業創新藥亞甲藍腸溶緩釋片中國橋接試驗完成首例受試者給藥,這是繼該產品2021年8月中國IND獲批後的又一重大進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account